Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Falling Comet
2470.1500 -24.55 (-0.98%)
NSE Apr 09, 2025 15:31 PM
Volume: 44,392
 

logo
Ajanta Pharma Ltd.
01 Aug 2018
2470.15
-0.98%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 8% YoY to | 511.0 crore (I-direct estimate: | 473.6 crore) mainly due to 24.5% YoY growth in domestic formulations to | 178.0 crore (I-direct estimate: | 175.0 crore) and 34.4% growth in Asia business to | 129 crore (I-direct estimate: | 134 crore) EBITDA margins improved 320 bps YoY to 30.8% (I-direct estimate: 25.8%) mainly due to strong gross margins and lower other expenditure. EBITDA grew 20.5% YoY to | 157.5 crore...
Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.
More from Ajanta Pharma Ltd.
Recommended